In the field of precision therapy, combining AI-driven tumor neoantigen prediction with CRISPR technology to screen high-affinity carriers (e.g., Bifidobacterium delivering KRAS mutant antigens) will promote breakthroughs in personalized vaccines, activating specific anti-tumor immune responses through customized antigen delivery to overcome tumor heterogeneity limitations. This evidence concerns the gene KRAS and neoplasm.